Pretreatment financial toxicity predicts progression-free survival following concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer

Research output: Contribution to journalArticle

Abstract

Aim: Financial toxicity (FT) describes patients' burden from out-of-pocket medical treatment costs. We studied associations between patient-reported pretreatment FT, socioeconomic status and clinical outcomes for locally advanced non-small-cell lung cancer (LA-NSCLC) patients. Methods: Patients received chemoradiotherapy for locally advanced non-small-cell lung cancer and completed the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) quality of life assessment before treatment. One question asks whether patients experience financial difficulties'. We tested FT and socioeconomic status (SES) as predictors of progression-free survival (PFS) and overall survival (OS). Results: A total of 43 patients were included. Median follow-up for surviving patients was 15 months. A total of 19 patients (44%) experienced disease progression and 17 patients (40%) died. Increasing FT was associated with shorter PFS (p = 0.011). FT did not predict overall survival (p = 0.67). Conclusion: Higher pretreatment FT is associated with shorter PFS.

Original languageEnglish (US)
Pages (from-to)1697-1705
Number of pages9
JournalFuture Oncology
Volume15
Issue number15
DOIs
StatePublished - May 1 2019

Fingerprint

Chemoradiotherapy
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Social Class
Quality of Life
Survival
Health Care Costs
Disease Progression
Organizations
Therapeutics
Research

Keywords

  • chemoradiotherapy
  • chemotherapy
  • financial toxicity
  • lung cancer
  • non-small-cell lung cancer
  • quality of life
  • radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{754bee18916044f7aebaebe490e9d946,
title = "Pretreatment financial toxicity predicts progression-free survival following concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer",
abstract = "Aim: Financial toxicity (FT) describes patients' burden from out-of-pocket medical treatment costs. We studied associations between patient-reported pretreatment FT, socioeconomic status and clinical outcomes for locally advanced non-small-cell lung cancer (LA-NSCLC) patients. Methods: Patients received chemoradiotherapy for locally advanced non-small-cell lung cancer and completed the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) quality of life assessment before treatment. One question asks whether patients experience financial difficulties'. We tested FT and socioeconomic status (SES) as predictors of progression-free survival (PFS) and overall survival (OS). Results: A total of 43 patients were included. Median follow-up for surviving patients was 15 months. A total of 19 patients (44{\%}) experienced disease progression and 17 patients (40{\%}) died. Increasing FT was associated with shorter PFS (p = 0.011). FT did not predict overall survival (p = 0.67). Conclusion: Higher pretreatment FT is associated with shorter PFS.",
keywords = "chemoradiotherapy, chemotherapy, financial toxicity, lung cancer, non-small-cell lung cancer, quality of life, radiation therapy",
author = "Klein, {Jonathan H.} and Bodner, {William R.} and Garg, {Madhur K.} and Shalom Kalnicki and Nitin Ohri",
year = "2019",
month = "5",
day = "1",
doi = "10.2217/fon-2018-0874",
language = "English (US)",
volume = "15",
pages = "1697--1705",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "15",

}

TY - JOUR

T1 - Pretreatment financial toxicity predicts progression-free survival following concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer

AU - Klein, Jonathan H.

AU - Bodner, William R.

AU - Garg, Madhur K.

AU - Kalnicki, Shalom

AU - Ohri, Nitin

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Aim: Financial toxicity (FT) describes patients' burden from out-of-pocket medical treatment costs. We studied associations between patient-reported pretreatment FT, socioeconomic status and clinical outcomes for locally advanced non-small-cell lung cancer (LA-NSCLC) patients. Methods: Patients received chemoradiotherapy for locally advanced non-small-cell lung cancer and completed the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) quality of life assessment before treatment. One question asks whether patients experience financial difficulties'. We tested FT and socioeconomic status (SES) as predictors of progression-free survival (PFS) and overall survival (OS). Results: A total of 43 patients were included. Median follow-up for surviving patients was 15 months. A total of 19 patients (44%) experienced disease progression and 17 patients (40%) died. Increasing FT was associated with shorter PFS (p = 0.011). FT did not predict overall survival (p = 0.67). Conclusion: Higher pretreatment FT is associated with shorter PFS.

AB - Aim: Financial toxicity (FT) describes patients' burden from out-of-pocket medical treatment costs. We studied associations between patient-reported pretreatment FT, socioeconomic status and clinical outcomes for locally advanced non-small-cell lung cancer (LA-NSCLC) patients. Methods: Patients received chemoradiotherapy for locally advanced non-small-cell lung cancer and completed the European Organization for the Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) quality of life assessment before treatment. One question asks whether patients experience financial difficulties'. We tested FT and socioeconomic status (SES) as predictors of progression-free survival (PFS) and overall survival (OS). Results: A total of 43 patients were included. Median follow-up for surviving patients was 15 months. A total of 19 patients (44%) experienced disease progression and 17 patients (40%) died. Increasing FT was associated with shorter PFS (p = 0.011). FT did not predict overall survival (p = 0.67). Conclusion: Higher pretreatment FT is associated with shorter PFS.

KW - chemoradiotherapy

KW - chemotherapy

KW - financial toxicity

KW - lung cancer

KW - non-small-cell lung cancer

KW - quality of life

KW - radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=85065993650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065993650&partnerID=8YFLogxK

U2 - 10.2217/fon-2018-0874

DO - 10.2217/fon-2018-0874

M3 - Article

VL - 15

SP - 1697

EP - 1705

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 15

ER -